Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

Abhinav Deol, MD, physician, Karmanos Cancer Institute, associate professor, Clinical Hematology and Oncology, Wayne State University, discusses the importance of communication and collaboration in CAR T-cell therapy.

Collaboration between transplant centers and physicians in the community is important to ensure patients are referred to treatment as early as possible to plan for CAR T-cell therapy, Deol says. At Karmanos Cancer Institute, a community of physicians work remain in constant communication during the evaluation of patients for transplant or cellular therapy, the administration of bridging therapy, and the transition from CAR T-cell therapy back to community care, Deol explains.

Since CAR T-cell therapies are associated with unique toxicities, it is important for patients and caregivers to be well informed about the treatment, Deol continues. If patients and clinicians can identify toxicities early, more time is available to mitigate any adverse effects that are experienced, Deol concludes.